Cancer clinical trials in the region Occitanie
386 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Colon cancer
Rectal cancer
#NCT06997497
#2024-517232-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06456346
#2023-505232-36-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Essential thrombocythemia
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Cytoreductive therapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06510374
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
10 recruiting sites
Ferring Pharmaceuticals
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06499285
#2024-516009-22-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
EPO / Growth factors
Required medullary blasts
< 5 %
Required transfusion dependency statuses
Transfusion-dependent
Required IPSS-R prognostic scores
Very low
Low
Intermediate
Excluded previous treatments
Systemic Treatment-Naive
Chemotherapy
Allogeneic stem cell transplant
Erythroid maturation agent
4 recruiting sites
Takeda
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06479135
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
14 recruiting sites
Kartos Therapeutics
Phase 3
Lung cancer
#NCT06692738
#2024-514281-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT06966700
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Radiotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Radiotherapy
Hormone therapy
7 recruiting sites
Merck Sharp & Dohme LLC